BioEclosion Company Profile

Background

Overview

BioEclosion, established in 2016 as a spin-off from the Universitat Autònoma de Barcelona (UAB), specializes in developing portable diagnostics that deliver laboratory-quality results within minutes. The company focuses on providing rapid, accurate diagnostics in settings lacking access to traditional laboratory infrastructure, such as remote or resource-limited environments. Their mission is to make high-precision diagnostics fast, affordable, and accessible to anyone, anywhere.

Mission and Vision

BioEclosion's mission is to translate frontier biomedical research into portable diagnostics that deliver answers in minutes, where they matter most. Their vision is to set the standard for 10-minute diagnostics, providing lab-grade results across human, veterinary, and food-safety markets.

Primary Area of Focus

The company's primary focus is on developing rapid diagnostic solutions for human health, veterinary diagnostics, food safety, and environmental monitoring. By leveraging their patented biosensing platform, BioEclosion aims to address the challenges associated with traditional diagnostic methods, particularly in low-resource settings.

Industry Significance

In the diagnostics industry, BioEclosion stands out by offering a versatile platform capable of delivering rapid, accurate results across various sectors. Their technology addresses critical needs in global health, particularly in regions with limited access to conventional diagnostic facilities. By providing timely diagnostics, BioEclosion contributes to improved disease management, food safety, and environmental monitoring.

Key Strategic Focus

Core Objectives

• Rapid Diagnostics: Develop and deploy diagnostic solutions that provide results within minutes, enabling swift decision-making.

• Accessibility: Ensure diagnostics are affordable and accessible, particularly in low-resource and decentralized settings.

• Versatility: Create a platform adaptable to various applications, including human health, veterinary diagnostics, food safety, and environmental monitoring.

Specific Areas of Specialization

• Point-of-Care Testing: Design diagnostics that can be used at the point of care, eliminating the need for centralized laboratories.

• Biosensing Technology: Utilize advanced biosensing platforms to detect a wide range of pathogens and biomarkers.

• Rapid Result Delivery: Focus on providing quantitative results in a short timeframe, typically within 10 minutes.

Key Technologies Utilized

• Magneto-Electrochemical Sensors: Employ sensors that combine magnetic particles with electrochemical detection to achieve high sensitivity and specificity.

• Isothermal Amplification (AmpliFast): Implement a proprietary amplification method that allows for the detection of DNA or RNA without the need for thermal cycling equipment.

• Portable Readers: Develop battery-powered, handheld devices that interface with smartphones or tablets to display results.

Primary Markets Targeted

• Human Health: Provide diagnostics for infectious diseases, chronic conditions, and other health concerns.

• Veterinary Diagnostics: Offer solutions for animal health, including disease detection and monitoring.

• Food Safety: Ensure the safety of food products by detecting contaminants and pathogens.

• Environmental Monitoring: Monitor environmental samples for pollutants and pathogens to safeguard ecosystems and public health.

Financials and Funding

Funding History

BioEclosion has secured funding through various channels, including European research grants and strategic support from investment firms. Notably, Addenda Capital has been a strategic supporter, contributing to the company's growth and development.

Total Funds Raised

Specific details regarding the total funds raised by BioEclosion are not publicly disclosed.

Recent Funding Rounds

Information about recent funding rounds is not publicly available.

Notable Investors

• Addenda Capital: An independent investment firm that has provided strategic support to BioEclosion.

Intended Utilization of Capital

The capital raised is intended to support BioEclosion's research and development efforts, expand its product portfolio, and enhance its market presence in the diagnostics industry.

Pipeline Development

Key Pipeline Candidates

• CeliFast: A diagnostic test that replaces intestinal biopsy with a finger-stick blood test for coeliac disease.

• AmpliSenS / AmpliFast: Screening tests for pregnant women and neonates for group B streptococcal sepsis at the point of care.

• AviaSenS: A test that detects avian influenza, Newcastle disease, and infectious bronchitis virus directly on poultry farms, enabling same-day biosecurity action.

• EChiLiBRiST: A €6.5 million Horizon Europe consortium that validates a multiplex cartridge for stratifying pediatric fever severity across three African countries to improve triage and antibiotic stewardship.

Stages of Clinical Trials or Product Development

The company is actively involved in the development and validation of these diagnostic tests, with some products undergoing clinical trials and others in the process of commercialization.

Target Conditions

• CeliFast: Coeliac disease.

• AmpliSenS / AmpliFast: Group B streptococcal sepsis.

• AviaSenS: Avian influenza, Newcastle disease, and infectious bronchitis virus.

• EChiLiBRiST: Pediatric fever severity.

Relevant Timelines for Anticipated Milestones

Specific timelines for product development milestones are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

• Magneto-Electrochemical Sensors: These sensors combine magnetic particles with electrochemical detection to achieve high sensitivity and specificity in diagnostics.